Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.

Haematologica - 1 Sept 2014

Nielsen Camilla, Bojesen Stig E, Nordestgaard Børge G, Kofoed Klaus F, Birgens Henrik S

Abstract excerpt

Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without overt signs of myeloproliferative disease....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Denmark
Share to Erythrocyte Indices

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoietin

Share to Hematologic Neoplasms

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Platelet Count

Source

Open in PubMed Open full text

Identifiers

PMID: 24907356
DOI: 10.3324/haematol.2014.107631
PMCID: PMC4562533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24907356-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.PMID 24907356Read ↗

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.Semantic proximity Read ↗

JAK2 V617F Mutational Burden and Clinical Findings Relationship in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Semantic proximity Read ↗

JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kineticsSemantic proximity Read ↗

Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype.Semantic proximity Read ↗

Genetics: Myeloproliferative neoplasms—order of mutations counts!Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.Semantic proximity Read ↗

Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.